Tesamorelin
Egrifta
An FDA-approved GHRH analog indicated for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
At a glance
- Category
- Growth Hormone
- Half-life
- ~24 minutes
- Typical vial sizes
- 1 mg · 2 mg
- Commonly cited dose
- 1000–2000 mcg
- Frequency
- once daily
- Routes
- Subcutaneous
A 1 mg vial, worked through.
Reconstituting a 1 mg vial of Tesamorelin with 2 mL of bacteriostatic water gives 0.5 mg/mL. A 1000 mcg dose is then:
- 200 units will not fit in a 1 mL syringe (100 units). Use more concentrated mixing, or split the dose.
Storage
- Lyophilised (unmixed)
- Refrigerated per product labelling.
- Reconstituted
- Use promptly; follow the product labelling.
What people log it against
Outcomes users commonly track alongside this compound. Listing them is not a claim that it produces them.
- Visceral fat reduction (approved indication)
References
The figures on this page have not yet been verified against primary literature. Treat them as provisional and confirm against a primary source before relying on them.
Run your own numbers
Pick Tesamorelin from the preset list to start from a typical vial.
As printed on the vial label
How much you inject into the vial
1000 mcg = 1 mg
Fills in a common vial size and the low end of commonly cited protocols. Always check against your own vial.
on a 1 mL U-100 insulin syringe
- Concentration
- 5 mg/mL
- Volume
- 0.05 mL
- Doses in this vial
- 40
VialPal does the arithmetic — it does not tell you what to take. Dose decisions belong between you and a qualified clinician.